Related references
Note: Only part of the references are listed.Reduced oxygenation but not fibrosis defined by functional magnetic resonance imaging predicts the long-term progression of chronic kidney disease
Kei Sugiyama et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes-2020
DIABETES CARE (2020)
Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice
Mai Sugahara et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
The oral hypoxia-inducible factor prolyl hydroxylase inhibitor enarodustat counteracts alterations in renal energy metabolism in the early stages of diabetic disease
Sho Hasegawa et al.
KIDNEY INTERNATIONAL (2020)
Innate immunity in diabetic kidney disease
Sydney C. W. Tang et al.
NATURE REVIEWS NEPHROLOGY (2020)
The role of renal hypoxia in the pathogenesis of diabetic kidney disease: a promising target for newer renoprotective agents including SGLT2 inhibitors?
Anne C. Hesp et al.
KIDNEY INTERNATIONAL (2020)
Bardoxolone methyl: drug development for diabetic kidney disease
Hironori Kanda et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2020)
SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition
Issei Tomita et al.
CELL METABOLISM (2020)
Randomized Clinical Trial on the Effect of Bardoxolone Methyl on GFR in Diabetic Kidney Disease Patients (TSUBAKI Study)
Masaomi Nangaku et al.
KIDNEY INTERNATIONAL REPORTS (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes
George L. Bakris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Targeting Inflammation in Diabetic Kidney Disease: Is There a Role for Pentoxifylline?
David J. Leehey
KIDNEY360 (2020)
The Global Burden of Diabetic Kidney Disease: Time Trends and Gender Gaps
Bernadette Thomas
CURRENT DIABETES REPORTS (2019)
Epigenetics and epigenomics in diabetic kidney disease and metabolic memory
Mitsuo Kato et al.
NATURE REVIEWS NEPHROLOGY (2019)
Nonproteinuric Versus Proteinuric Phenotypes in Diabetic Kidney Disease: A Propensity Score-Matched Analysis of a Nationwide, Biopsy-Based Cohort Study
Masayuki Yamanouchi et al.
DIABETES CARE (2019)
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
Hiddo J. L. Heerspink et al.
LANCET (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Esaxerenone (CS-3150) for the Treatment of Type 2 Diabetes with Microalbuminuria: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial
Sadayoshi Ito et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C. Gerstein et al.
LANCET (2019)
Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience
Neil S. Sanghani et al.
ADVANCES IN CHRONIC KIDNEY DISEASE (2019)
Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition
Pouya Saeedi et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Effects of Selonsertib in Patients with Diabetic Kidney Disease
Glenn M. Chertow et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function
Giuseppe Pugliese et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2019)
Clinical features and long-term outcomes of diabetic kidney disease - A prospective cohort study from China
Bixia Gao et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2019)
Histone demethylase UTX is a therapeutic target for diabetic kidney disease
Hong Chen et al.
JOURNAL OF PHYSIOLOGY-LONDON (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
MicroRNAs as therapeutic targets for the treatment of diabetes mellitus and its complications
Romano Regazzi
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Complement C5a inhibition moderates lipid metabolism and reduces tubulointerstitial fibrosis in diabetic nephropathy
Wai Han Yiu et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
The Global Epidemiology of Diabetes and Kidney Disease
Digsu N. Koye et al.
ADVANCES IN CHRONIC KIDNEY DISEASE (2018)
Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study
Giuseppe Penno et al.
DIABETOLOGIA (2018)
The association between estimated glomerular filtration rate, albuminuria, and risk of cardiovascular hospitalizations and all-cause mortality among patients with type 2 diabetes
Gregory A. Nichols et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2018)
Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease
Menno Pruijm et al.
KIDNEY INTERNATIONAL (2018)
Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice
Shinji Tanaka et al.
KIDNEY INTERNATIONAL (2018)
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
Katherine R. Tuttle et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2018)
Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice
Michitsugu Kamezaki et al.
SCIENTIFIC REPORTS (2018)
Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R. Tuttle et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
ASK1 contributes to fibrosis and dysfunction in mode of kidney disease
John T. Liles et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice
Yifan Zhang et al.
KIDNEY INTERNATIONAL (2018)
Aberrant DNA methylation of Tgfb1 in diabetic kidney mesangial cells
Shigeyoshi Oba et al.
SCIENTIFIC REPORTS (2018)
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
Marcel H. A. Muskiet et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Mineralocorticoid receptor antagonists: 60 years of research and development
Peter Kolkhof et al.
JOURNAL OF ENDOCRINOLOGY (2017)
Prolyl hydroxylase domain inhibitors as a novel therapeutic approach against anemia in chronic kidney disease
Mai Sugahara et al.
KIDNEY INTERNATIONAL (2017)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Liraglutide and Renal Outcomes in Type 2 Diabetes
Johannes F. E. Mann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Non-proteinuric diabetic nephropathy is the main cause of chronic kidney disease: Results of a general population survey in Spain
N. R. Robles et al.
DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS (2017)
Impaired Podocyte Autophagy Exacerbates Proteinuria in Diabetic Nephropathy
Atsuko Tagawa et al.
DIABETES (2016)
Diabetes and Kidney Disease: Role of Oxidative Stress
Jay C. Jha et al.
ANTIOXIDANTS & REDOX SIGNALING (2016)
SGLT2 Inhibitors and the Diabetic Kidney
Paola Fioretto et al.
DIABETES CARE (2016)
Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014
Maryam Afkarian et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Cardiovascular and all-cause mortality in patients with type 2 diabetes mellitus in the MADIABETES Cohort Study: Association with chronic kidney disease
Miguel Angel Salinero-Fort et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2016)
Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress
Wai Han Yiu et al.
KIDNEY INTERNATIONAL (2016)
Nephron Protection in Diabetic Kidney Disease
Hans-Joachim Anders et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Steven P. Marso et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Role of NADPH Oxidase in Metabolic Disease-Related Renal Injury: An Update
Cheng Wan et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2016)
Epigenomic profiling reveals an association between persistence of DNA methylation and metabolic memory in the DCCT/EDIC type 1 diabetes cohort
Zhuo Chen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Pronounced kidney hypoxia precedes albuminuria in type 1 diabetic mice
Stephanie Franzen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2016)
ASK1: a new therapeutic target for kidney disease
Greg H. Tesch et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2016)
ASK1 Inhibitor Halts Progression of Diabetic Nephropathy in Nos3-Deficient Mice
Greg H. Tesch et al.
DIABETES (2015)
Progressive Renal Decline: The New Paradigm of Diabetic Nephropathy in Type 1 Diabetes
Andrzej S. Krolewski
DIABETES CARE (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Autophagy: A Novel Therapeutic Target for Diabetic Nephropathy
Shinji Kume et al.
DIABETES & METABOLISM JOURNAL (2015)
Autophagy in diabetic nephropathy
Yan Ding et al.
JOURNAL OF ENDOCRINOLOGY (2015)
Effect of Pentoxifylline on Renal Function and Urinary Albumin Excretion in Patients with Diabetic Kidney Disease: The PREDIAN Trial
Juan F. Navarro-Gonzalez et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Activation of Hypoxia-Inducible Factors Prevents Diabetic Nephropathy
Lina Nordquist et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Risk Factors for Heart Failure in Patients With Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease Treated With Bardoxolone Methyl
Melanie P. Chin et al.
JOURNAL OF CARDIAC FAILURE (2014)
The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy
Dick de Zeeuw et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
The Nrf2 pathway in the progression of renal disease
Carlamaria Zoja et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2014)
Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study
Ian H. de Boer et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Normoalbuminuric Diabetic Kidney Disease in the US Population
Amy K. Mottl et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2013)
Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy
Linda F. Fried et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
Dick de Zeeuw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Toll-Like Receptor 4 Promotes Tubular Inflammation in Diabetic Nephropathy
Miao Lin et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study
Jamie P. Dwyer et al.
CARDIORENAL MEDICINE (2012)
Antidiuretic effects of the endothelin receptor antagonist avosentan
Ovidiu Constantin Baltatu et al.
FRONTIERS IN PHYSIOLOGY (2012)
Effect of Bardoxolone Methyl on Kidney Function in Patients with T2D and Stage 3b-4 CKD
Pablo E. Pergola et al.
AMERICAN JOURNAL OF NEPHROLOGY (2011)
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice
Markus Goedel et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Pirfenidone for Diabetic Nephropathy
Kumar Sharma et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Angiotensin II revisited: new roles in inflammation, immunology and aging
Ariela Benigni et al.
EMBO MOLECULAR MEDICINE (2010)
Evaluation of Renal Hypoxia in Diabetic Mice by BOLD MRI
Pottumarthi Prasad et al.
INVESTIGATIVE RADIOLOGY (2010)
Avosentan for Overt Diabetic Nephropathy
Johannes F. E. Mann et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2010)
The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential
Hiroyuki Mori et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Enhanced Expression of Janus Kinase-Signal Transducer and Activator of Transcription Pathway Members in Human Diabetic Nephropathy
Celine C. Berthier et al.
DIABETES (2009)
Pirfenidone Is Renoprotective in Diabetic Kidney Disease
Satish P. RamachandraRao et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Avosentan Reduces Albumin Excretion in Diabetics with Macroalbuminuria
Rene R. Wenzel et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2009)
Adaptation to hypoxia in the diabetic rat kidney
C. Rosenberger et al.
KIDNEY INTERNATIONAL (2008)
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study):: a multicentre, randomised, double-blind, controlled trial
Johannes F. E. Mann et al.
LANCET (2008)
Risk factors for renal dysfunction in type 2 diabetes - UK prospective diabetes study 74
Ravi Retnakaran et al.
DIABETES (2006)
Chronic hypoxia and tubulointerstitial injury: A final common pathway to end-stage renal failure
Masaomi Nangaku
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2006)
Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension
F Palm et al.
DIABETOLOGIA (2003)
Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
AI Adler et al.
KIDNEY INTERNATIONAL (2003)
Interaction of MAPK and 12-lipoxygenase pathways in growth and matrix protein expression in mesangial cells
MA Reddy et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2002)
Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
BM Brenner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
EJ Lewis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
HH Parving et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Effects of endothelin receptor antagonists on the progression of diabetic nephropathy
B Hocher et al.
NEPHRON (2001)
Share Paper
